Financial reports
ARS
2023 FY
Annual report to shareholders
19 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
19 Mar 24
8-K
Other Events
26 Jan 24
8-K
Results of Operations and Financial Condition
24 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
14 Dec 23
8-K
Departure of Directors or Certain Officers
30 Nov 23
8-K
Index to Unaudited Condensed Financial Statements
14 Nov 23
8-K
Departure of Directors or Certain Officers
27 Oct 23
8-K
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
19 Oct 23
8-K
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
17 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
19 Mar 24
424B5
Prospectus supplement for primary offering
26 Jan 24
424B5
Prospectus supplement for primary offering
24 Jan 24
S-8
Registration of securities for employees
20 Oct 23
425
Business combination disclosure
10 Oct 23
425
Business combination disclosure
10 Oct 23
425
Business combination disclosure
6 Oct 23
425
Business combination disclosure
26 Sep 23
424B3
Prospectus supplement
15 Sep 23
Other
EFFECT
Notice of effectiveness
15 Sep 23
SEC STAFF LETTER
SEC staff letter
14 Sep 23
CORRESP
Correspondence with SEC
13 Sep 23
CORRESP
Correspondence with SEC
11 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
CORRESP
Correspondence with SEC
25 Aug 23
SEC STAFF LETTER
SEC staff letter
16 Aug 23
UPLOAD
Letter from SEC
16 Aug 23
EFFECT
Notice of effectiveness
26 Aug 22
CORRESP
Correspondence with SEC
23 Aug 22
Ownership
SC 13G/A
PFIZER INC
15 Mar 24
SC 13G/A
Hydra LLC
14 Feb 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Blackstone Holdings II L.P.
9 Feb 24
SC 13G
TCG Crossover GP I, LLC
9 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
MARK MCDADE
31 Jan 24
4
CLAY B SIEGALL
15 Dec 23